{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:12:25Z","timestamp":1785417145238,"version":"3.56.0"},"posted":{"date-parts":[[2026,3,11]]},"group-title":"Cancer Biology","reference-count":79,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["W81XWH-22-1-0265"],"award-info":[{"award-number":["W81XWH-22-1-0265"]}],"id":[{"id":"https:\/\/ror.org\/03g2zjp07","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R35GM124913"],"award-info":[{"award-number":["R35GM124913"]}],"id":[{"id":"https:\/\/ror.org\/04q48ey07","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive sarcomas with poor prognosis and a strong tendency for metastasis and relapse. Surgical removal remains the mainstay of treatment but is frequently ineffective or impractical. Currently, no effective targeted therapy exists for this type of malignancy. PRMT5 has recently emerged as a promising therapeutic target in various human cancers with MTAP loss, which results in cancer cell dependency on PRMT5 activity. The frequent loss of MTAP in MPNSTs suggests that PRMT5 inhibition is a promising therapeutic option and enables the stratification of cancer patients with few treatment options. We first examined human nerve sheath tumor samples and found that increased PRMT5 expression and activity correlated with MTAP loss in 86.8% (33\/38) of MPNSTs and in atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP) (5\/5). When PRMT5 activity was inhibited genetically and chemically, the cell growth of MTAP-deficient MPNST cell lines was suppressed, but not that of MTAP-proficient MPNST cell lines. Moreover, in the PRMT5-inhibited MTAP-deficient MPNST cell lines, spontaneous DNA damage accumulation was observed following G2\/M cell cycle arrest. The DNA replication stress marker RPA32 decreased, and CHK1 was activated early after PRMT5 knockdown, likely contributing to the accumulation of DNA damage. In addition, we combined PRMT5 inhibition with the DNA-damaging agents doxorubicin and gemcitabine, resulting in synergistic effects and increased cancer cell death in MTAP-deficient MPNST cell lines. Together, these findings identify PRMT5 as a compelling therapeutic target in MTAP-deficient MPNSTs. This PRMT5 inhibition strategy has strong translational potential for MPNSTs.<\/jats:p>\n                <jats:sec>\n                  <jats:title>GRAPHICAL ABSTRACT<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"710638v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.64898\/2026.03.09.710638","type":"posted-content","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:50:18Z","timestamp":1773283818000},"source":"Crossref","is-referenced-by-count":0,"title":["PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3827-620X","authenticated-orcid":false,"given":"Dingxun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Comparative Pathobiology;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-6382","authenticated-orcid":false,"given":"Melissa L.","family":"Fishel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine."},{"name":"Indiana University School of Medicine, Department of Biochemistry, Molecular Biology & Pharmacology;"},{"name":"Indiana University Simon Comprehensive Cancer Center (IUSCCC);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Samiei","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mayo Clinic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silpa","family":"Gampala","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine."},{"name":"Indiana University Simon Comprehensive Cancer Center (IUSCCC);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changdeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Molecular Pharmacology."},{"name":"Purdue Institute for Cancer Research."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxiong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Indiana University School of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0839-5161","authenticated-orcid":false,"given":"GuangJun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Comparative Pathobiology;"},{"name":"Purdue Institute for Cancer Research."},{"name":"Purdue Institute for Inflammation, Immunology, and Infectious Diseases."},{"name":"Purdue Institute for Integrative Neuroscience."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026031315401902000_2026.03.09.710638v1.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0954-z"},{"key":"2026031315401902000_2026.03.09.710638v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0748-7983(05)80073-3"},{"key":"2026031315401902000_2026.03.09.710638v1.3","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399409001227"},{"issue":"Suppl 1","key":"2026031315401902000_2026.03.09.710638v1.4","first-page":"i50","article-title":"Genetics of human malignant peripheral nerve sheath tumors","volume":"2","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026031315401902000_2026.03.09.710638v1.5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0786"},{"key":"2026031315401902000_2026.03.09.710638v1.6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1429"},{"key":"2026031315401902000_2026.03.09.710638v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/NEUONC\/NOZ028"},{"key":"2026031315401902000_2026.03.09.710638v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/375503a0"},{"key":"2026031315401902000_2026.03.09.710638v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81401-4"},{"key":"2026031315401902000_2026.03.09.710638v1.10","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181e9c08a"},{"key":"2026031315401902000_2026.03.09.710638v1.11","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/756395"},{"key":"2026031315401902000_2026.03.09.710638v1.12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-3-319-30654-4_22","article-title":"Malignant Peripheral Nerve Sheath Tumors","volume":"916","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"2026031315401902000_2026.03.09.710638v1.13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0328"},{"key":"2026031315401902000_2026.03.09.710638v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.144"},{"issue":"15","key":"2026031315401902000_2026.03.09.710638v1.15","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-21-3760","article-title":"The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents","volume":"28","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026031315401902000_2026.03.09.710638v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00864-3"},{"key":"2026031315401902000_2026.03.09.710638v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0046-z"},{"key":"2026031315401902000_2026.03.09.710638v1.18","doi-asserted-by":"crossref","unstructured":"Goncalves E , Ryan CJ , Adams DJ . Synthetic lethality in cancer drug discovery: challenges and opportunities. Nat Rev Drug Discov. 2025.","DOI":"10.1038\/s41573-025-01273-7"},{"issue":"3","key":"2026031315401902000_2026.03.09.710638v1.19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.trecan.2015.10.002","article-title":"Collateral Lethality: A new therapeutic strategy in oncology","volume":"1","year":"2015","journal-title":"Trends Cancer"},{"key":"2026031315401902000_2026.03.09.710638v1.20","doi-asserted-by":"crossref","unstructured":"Zhao Z , Zhu L , Luo Y , Xu H , Zhang Y . Collateral lethality: A unique type of synthetic lethality in cancers. Pharmacol Ther. 2025; 265:108755.","DOI":"10.1016\/j.pharmthera.2024.108755"},{"key":"2026031315401902000_2026.03.09.710638v1.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0669"},{"key":"2026031315401902000_2026.03.09.710638v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5214"},{"key":"2026031315401902000_2026.03.09.710638v1.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5944"},{"key":"2026031315401902000_2026.03.09.710638v1.24","doi-asserted-by":"publisher","DOI":"10.1042\/bj1150241"},{"key":"2026031315401902000_2026.03.09.710638v1.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.12.6203"},{"key":"2026031315401902000_2026.03.09.710638v1.26","doi-asserted-by":"publisher","DOI":"10.15698\/cst2020.08.228"},{"key":"2026031315401902000_2026.03.09.710638v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00613-y"},{"key":"2026031315401902000_2026.03.09.710638v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3409"},{"key":"2026031315401902000_2026.03.09.710638v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102961"},{"key":"2026031315401902000_2026.03.09.710638v1.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0092"},{"key":"2026031315401902000_2026.03.09.710638v1.31","doi-asserted-by":"crossref","first-page":"20406207241275376","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"2026031315401902000_2026.03.09.710638v1.32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31909"},{"issue":"6","key":"2026031315401902000_2026.03.09.710638v1.33","first-page":"e70150","article-title":"PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5\/C-Myc Feedback Loop","volume":"6","year":"2025","journal-title":"MedComm (2020)"},{"issue":"8","key":"2026031315401902000_2026.03.09.710638v1.34","doi-asserted-by":"crossref","first-page":"e17248","DOI":"10.15252\/emmm.202217248","article-title":"Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERalpha(+) breast cancer","volume":"15","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"8","key":"2026031315401902000_2026.03.09.710638v1.35","first-page":"716","article-title":"Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"2026031315401902000_2026.03.09.710638v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01270-8"},{"issue":"1","key":"2026031315401902000_2026.03.09.710638v1.37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s10020-025-01353-9","article-title":"Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors","volume":"31","year":"2025","journal-title":"Mol Med"},{"key":"2026031315401902000_2026.03.09.710638v1.38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1992"},{"key":"2026031315401902000_2026.03.09.710638v1.39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg8876"},{"key":"2026031315401902000_2026.03.09.710638v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/srep40325"},{"issue":"1","key":"2026031315401902000_2026.03.09.710638v1.41","doi-asserted-by":"crossref","first-page":"100750","DOI":"10.1016\/j.isci.2019.100750","article-title":"PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes","volume":"23","year":"2020","journal-title":"iScience"},{"key":"2026031315401902000_2026.03.09.710638v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0456-9"},{"key":"2026031315401902000_2026.03.09.710638v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.5"},{"key":"2026031315401902000_2026.03.09.710638v1.44","doi-asserted-by":"publisher","DOI":"10.1002\/pst.426"},{"key":"2026031315401902000_2026.03.09.710638v1.45","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0363-8"},{"key":"2026031315401902000_2026.03.09.710638v1.46","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw230"},{"issue":"2","key":"2026031315401902000_2026.03.09.710638v1.47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying Drug Combination Synergy along Potency and Efficacy Axes","volume":"8","year":"2019","journal-title":"Cell Syst"},{"key":"2026031315401902000_2026.03.09.710638v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRPHAR.2022.100110"},{"issue":"W1","key":"2026031315401902000_2026.03.09.710638v1.49","doi-asserted-by":"crossref","first-page":"W84","DOI":"10.1093\/nar\/gkaf402","article-title":"BioPortal: an open community resource for sharing, searching, and utilizing biomedical ontologies","volume":"53","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026031315401902000_2026.03.09.710638v1.50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41597-020-0508-5","article-title":"A clinically and genomically annotated nerve sheath tumor biospecimen repository","volume":"7","year":"2020","journal-title":"Sci Data"},{"key":"2026031315401902000_2026.03.09.710638v1.51","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx247"},{"key":"2026031315401902000_2026.03.09.710638v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07347-7"},{"key":"2026031315401902000_2026.03.09.710638v1.53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.235"},{"key":"2026031315401902000_2026.03.09.710638v1.54","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAB1061"},{"key":"2026031315401902000_2026.03.09.710638v1.55","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-021-03819-2"},{"issue":"4","key":"2026031315401902000_2026.03.09.710638v1.56","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/his.15502","article-title":"Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma","volume":"87","year":"2025","journal-title":"Histopathology"},{"key":"2026031315401902000_2026.03.09.710638v1.57","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0367"},{"key":"2026031315401902000_2026.03.09.710638v1.58","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0620"},{"key":"2026031315401902000_2026.03.09.710638v1.59","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01900"},{"key":"2026031315401902000_2026.03.09.710638v1.60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp516"},{"key":"2026031315401902000_2026.03.09.710638v1.61","doi-asserted-by":"crossref","unstructured":"He L , Urrutia G , Lomberk G . Inhibition of PRMT5 Disrupts Cell Cycle Progression and DNA Damage Signaling, Revealing a Potential Novel Combination Therapy for Pancreatic Cancer. The FASEB Journal. 2022; 36(S1).","DOI":"10.1096\/fasebj.2022.36.S1.0R678"},{"key":"2026031315401902000_2026.03.09.710638v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.08.002"},{"key":"2026031315401902000_2026.03.09.710638v1.63","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn550"},{"key":"2026031315401902000_2026.03.09.710638v1.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2005.01.029"},{"issue":"42","key":"2026031315401902000_2026.03.09.710638v1.65","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1038\/s41388-025-03583-x","article-title":"RAD51-mediated homologous recombination is a pro-tumour driver pathway","volume":"44","year":"2025","journal-title":"Oncogene"},{"key":"2026031315401902000_2026.03.09.710638v1.66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2014.06.002","article-title":"The Ku heterodimer: function in DNA repair and beyond","volume":"763","year":"2015","journal-title":"Mutat Res Rev Mutat Res"},{"key":"2026031315401902000_2026.03.09.710638v1.67","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2014.147"},{"issue":"3","key":"2026031315401902000_2026.03.09.710638v1.68","doi-asserted-by":"crossref","first-page":"zcaa022","DOI":"10.1093\/narcan\/zcaa022","article-title":"Replication protein A: a multifunctional protein with roles in DNA replication, repair and beyond","volume":"2","year":"2020","journal-title":"NAR Cancer"},{"key":"2026031315401902000_2026.03.09.710638v1.69","doi-asserted-by":"crossref","unstructured":"Nasheuer HP , Meaney AM , Hulshoff T , Thiele I , Onwubiko NO . Replication Protein A, the Main Eukaryotic Single-Stranded DNA Binding Protein, a Focal Point in Cellular DNA Metabolism. Int J Mol Sci. 2024; 25(1).","DOI":"10.3390\/ijms25010588"},{"key":"2026031315401902000_2026.03.09.710638v1.70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1479-5876-11-213","article-title":"Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors","volume":"11","year":"2013","journal-title":"J Transl Med"},{"key":"2026031315401902000_2026.03.09.710638v1.71","doi-asserted-by":"crossref","unstructured":"Seres R , Hameed H , McCabe MG , Russell D , Lee ATJ . The Multimodality Management of Malignant Peripheral Nerve Sheath Tumours. Cancers (Basel). 2024; 16(19).","DOI":"10.3390\/cancers16193266"},{"key":"2026031315401902000_2026.03.09.710638v1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.043"},{"issue":"1","key":"2026031315401902000_2026.03.09.710638v1.73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41420-025-02545-2","article-title":"Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models","volume":"11","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026031315401902000_2026.03.09.710638v1.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.01.019"},{"key":"2026031315401902000_2026.03.09.710638v1.75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009899117"},{"issue":"6","key":"2026031315401902000_2026.03.09.710638v1.76","doi-asserted-by":"crossref","first-page":"110250","DOI":"10.1016\/j.jbc.2025.110250","article-title":"Biochemical impact of p300-mediated acetylation of replication protein A: Implications for DNA metabolic pathway choice","volume":"301","year":"2025","journal-title":"J Biol Chem"},{"key":"2026031315401902000_2026.03.09.710638v1.77","doi-asserted-by":"crossref","unstructured":"Mueller HS , Fowler CE , Dalin S , et al. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. Proc Natl Acad Sci U S A. 2021; 118(34).","DOI":"10.1073\/pnas.2024055118"},{"issue":"11","key":"2026031315401902000_2026.03.09.710638v1.78","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","article-title":"PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies","volume":"3","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026031315401902000_2026.03.09.710638v1.79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46495-2"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.03.09.710638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:40:32Z","timestamp":1773441632000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.03.09.710638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":79,"URL":"https:\/\/doi.org\/10.64898\/2026.03.09.710638","relation":{},"subject":[],"published":{"date-parts":[[2026,3,11]]},"subtype":"preprint"}}